Mortality Rate and Survival Analysis among Hepatitis C Patients Ongoing Hemodialysis at Cempaka Putih Islamic Hospital, Jakarta – Indonesia
|
|
Author:
|
DIANA LAILA RAMATILLAH, DIMAS PANGESTU, MAIRO HAMID IPADEOLA, AFRIANA, IHSANIL HUSNA
|
Abstract:
|
The length of time a patient undergoes Hemodialysis (HD) is a factor related to the prevalence of HCV; this
may be related to an increased risk of exposure to HCV in the hospital environment, such as blood
transfusion, repeated vascular access, hygiene, and mixing room. So, The purpose of this research was to
evaluate the mortality rate and survival analysis among hemodialyzed patients with HCV.The study was
conducted by Cohort prospective and retrospective study at a hemodialysis center in Cempaka Putih Islamic
Hospital Jakarta, Indonesia. Participants who were included in this study were 111 patients (mean age 53, 67%
male, 33% Female). Participants of this study were HD patients with HCV who were followed up for three
months and patients who had died within the last five years from 2015-2019. Universal sampling was used to
select patients based on inclusion criteria. Male patients were predominant than female (64 patients). Almost
all sociodemography items had a significant correlation with the duration of hemodialysis except gender (P
>0,05). Around 95,65% HD patients were infected by hepatitis C after initiating hemodialysis. Most of HD
patients with hepatitis C had hypertensive (63,54%) and did not receive any hepatitis C treatment (66,67%).
Patients who received Daclatasvir and Sofubusvir had a 100% survival rate since the initiating of hemodialysis.
The study concluded that the mortality rate was high among HCV patients undergone HD without treatment
HCV, with about 8%. The highest survival rate was HD patients with hepatitis C undergoing treatment with daclatasvir + Sofosbuvir.
|
Keyword:
|
Hepatitis C, Hemodialysis, Complications, Mortality Rate, Survival Rate
|
EOI:
|
-
|
DOI:
|
https://doi.org/10.31838/ijpr/2021.13.02.360
|
Download:
|
Request For Article
|
|
|